Rivera-Tapia JA, Cedillo-Ramírez L, Lechuga-Licona LC, Fuentes-García G

Language: Spanish
References: 22
Page: 181-185
PDF size: 123.07 Kb.

ABSTRACT

Mycoplasmata are the smallest free-living microorganisms, being about 300 nm in diameter. They are bound by a triple-layered membrane, and unlike conventional bacteria, do not have a rigid cell wall. Hence, they are not susceptible to penicillins and other antibiotics that act on this structure. They are, however, susceptible to a variety of other broad-spectrum antibiotics, most of which only inhibit their multiplication and do not kill them. Objective: The activity in vitro of vancomycin, colistin, nistatin (VCN) and ciprofloxacin against mycoplasmata species was analyzed in this study, with the purpose to make their isolation possible. Material and methods: The MIC were determined by the metabolic inhibition method performed in 96-well microtiter plates. Results: MIC of the mycoplasmata species tested (µg/mL) were obtained for VCN (3.3, 7.5, 12.5) and ciprofloxacin (0.1-1 Mycoplasma fermentans and Mycoplasma pneumoniae) and (1-10 Mycoplasma penetrans). Conclusions: The viability of the mycoplasmata evaluated in presence of the antibiotics allows considering its addition to the cultures medium when isolation of clinical samples is required.

REFERENCES

1. Rivera TJA, Centeno TM, Santellan OR, Rodríguez PN. Prevalencia de Ureaplasma urealyticum en mujeres. Rev Mex Patol Clin 2004; 51: 33-36.

2. Garza-Velasco R, Vilchis-Gaona EG, Calderón-Ozumbilla F. Vancomicina y fluorquinolonas: Dos armas que aún conservan su eficacia dentro del oscuro panorama que envuelve a la terapéutica antimicrobiana. Disponible en: http://depa.pquim.unam.mx/bacteriologia/pdfs/ART%CDC-vancofluorq.pdf

3. Silva LE. Antifúngicos del futuro. Med Cutan Lat Am 2004; 32: 229-230.

4. Ullmann U, Schubert S, Krausse R. Comparative in vitro activity of levofloxacin, other fluorquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999; 43 (suppl C): 33-36.

5. Hooper DC. Expanding uses of fluorquinolones: opportunities and changes. Ann Inter Med 1998; 129: 908-910.

6. Rivera-Tapia JA, Cedillo-Ramírez ML, Vega-Benítez M. Micoplasmas y su importancia médica. Rev Biomed 2001; 12: 262-271.

7. Aldridge KE, Ashcraft D. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-711.

8. Woodcock J, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluorquinolone. Antimicrob Agents Chemother 1997; 41: 101-106.

9. Bebear CM, Renaudin H, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new fluorquinolone, against mycoplasmas. Antimicrob Agents Chemother 1998; 42: 703-704.

10. Pereyre S, Renaudin H, Bebear C, Bebear CM. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob Agents Chemother 2004; 48: 3165-3168.

11. Bebear CM, Renaudin H, Charron A, Gruson D, Lefrancois M, Bebear C. In vitro activity of trovafloxacine compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluorquinolone-resistance isolates that have been genetically characterized. Antimicrob Agents Chemother 2000; 44: 2557-2560.

12. Bebear CM, Renaudin H, Schaeverbeke T, Leblanc F, Bebear C. In-vitro activity of grepafloxacin, a new fluorquinolone, against mycoplasmas. J Antimicrob Chemother 1999; 43: 711-714.

13. Taylor-Robinson D, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmas infections. J Antimicrob Chemother 1997; 40: 622-630.

14. Hayes MM, Foo HH, Timenetsky J, Lo SC. In vitro antibiotic susceptibility testing of clinical isolates of Mycoplasma penetrans from patients with AIDS. Antimicrob Agents Chemother 1995; 39: 1386-1387.

15. Bebear CM, Renaudin H, Charron A, Bove JM, Bebear C, Renaudin J. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2304-2311.

16. Bebear CM, Renaudin J, Charron A, Renaudin H, Barbeyrac B, Schaeverbeke T, Bebear C. Mutation in the gyrA, parC, and parE genes associated with fluorquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother 1999; 43: 954-956.

17. Bebear CM, Bove JM, Bebear C, Renaudin J. Characterization of Mycoplasma hominis mutations involved in resistance to fluorquinolone. Antimicrob Agents Chemother 1997; 42: 269-273.

18. Muñoz-Bellido JL, Alonzo-Manzanares M, Martinez-Andres JA, Gutierrez Zufiaurre MN, Ortiz G, Segovia HM, Garcia RJA. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother 1999; 43: 354-356.

19. Piddock LJV, White DG, Gensberg K, Pumbwe L, Griggs DJ. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000; 44: 3118-3121.

20. Raherison S, Gonzalez P, Renaudin H, Charron A, Bebear C, Bebear CM. Increased expression of two multidrug transporter-like genes is associated with ethidium bromide and ciprofloxacin resistance in Mycoplasma hominis. Antimicrob Agents Chemother 2005; 49: 421-424.

21. Kenny G, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfoprisitn, and telithromycin compared to their susceptibilities to reference macrolides, tatracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-2608.

22. Duffy LB, Crabb D, Searcey K, Kempf MC. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother 2000; 45: 29-33.